Nav: Home

Blocking epigenetic Swiss army knife may be a new strategy for treating colorectal cancer

April 04, 2019

GRAND RAPIDS, Mich. (April 4, 2019) -- A new study out today in Cancer Cell shows that blocking specific regions of a protein called UHRF1 switches on hundreds of cancer-fighting genes, impairing colorectal cancer cells' ability to grow and spread throughout the body.

"Colorectal cancers are a growing public health problem, particularly in young people who haven't yet reached the recommended age for regular screening," said Scott Rothbart, Ph.D., an associate professor at Van Andel Research Institute (VARI) and co-corresponding author of the study. "UHRF1 has emerged in recent years as a key regulator of biological processes that drive colorectal cancer progression. This protein is akin to a molecular Swiss army knife, with many different parts that each have a different job. Revealing the parts that drive cancer progression could give us promising new ways to treat this disease."

Colorectal cancers are the third leading cause of cancer-related death among both men and women in the U.S. While overall rates have been falling since the mid-1980s, the decrease is largely driven by routine screening in older adults. In people ages 20 to 39, rates are actually increasing -- 1 to 2 percent a year between 1974 through 2013 for colon cancers and 3 percent per year between 1974 through 2013 for rectal cancers, according to a 2018 American Cancer Society report.

UHRF1 helps establish and maintain patterns of molecular tags on DNA, an epigenetic process known as methylation. These methylation patterns act like a switch that tells the body's cellular machinery when specific genes should be turned on or off. In cancer cells, these patterns change, impeding the normal checks-and-balances on cell growth and allowing malignant cells to flourish and spread.

UHRF1 is a tantalizing new target that complements an emerging class of drugs called DNA methyltransferase inhibitors (DNMTis), which have shown exceptional promise for correcting methylation errors and treating cancer. However, many of the compounds developed to date have not been able to penetrate a sufficient number of tumor cells simultaneously to fully repair methylation and reactivate anti-cancer genes.

"Epigenetic therapies are a promising avenue for cancer treatment, but we need new drugs that better reverse abnormal DNA methylation in patients' tumors with fewer side effects," said Stephen Baylin, M.D., co-corresponding author of the study, Director's Scholar at VARI and Virginia and D.K. Ludwig Professor for Cancer Research at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. "The strong anti-cancer effects that result when we block the regions of UHRF1 responsible for maintaining methylation are a critical step toward developing new, improved inhibitors for cancer treatment."

Identification of these regions on UHRF1 also may help better identify colorectal cancer subtypes, improving physician's ability to take a personalized approach to treatment. Using data provided by The Cancer Genome Atlas, a National Institutes of Health-led effort to molecularly map cancer, the team found a strong correlation between high levels of UHRF1 and more aggressive, tough-to-treat malignancies.

They now hope to translate their findings into actionable prognostic markers and, eventually, improved therapies that are more tolerable to patients and more effective at fighting cancer.

In addition to Rothbart and Baylin, Limin Xia, Ph.D., of Tongji Hospital also is co-corresponding author.
Other authors include Xiangqian Kong, Ph.D., Wenbing Xie, Ph.D., Stephen M. Brown, Yi Cai, Ph.D., Srinivasan Yegnasubramanian, M.D., Ph.D., Yong Tao, Ph.D., Ray-Whay Chiu Yen, M.S., Michael J. Topper, Cynthia A. Zahnow, Ph.D., and Hariharan Easwaran, M.Sc., Ph.D., of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Jie Chen, Kaichun Wu, M.D., Ph.D., Daiming Fan, M.D., Ph.D., and Yongzhan Nie, M.D., Ph.D., of State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University; and Rochelle Tiedemann, Ph.D., of Van Andel Research Institute. Kong, Chen and Xie are co-first authors. Chen also is affiliated with Tongji Hospital.

Research reported in this publication was supported by National Institute of Environmental Health Sciences award no. R01ES011858 (Baylin), National Institute of General Medical Sciences award no. R35GM124736 (Rothbart), National Natural Science Foundation of China award no. 81522031 (Xia) and no. 81772623 (Xia), National Key Research and Development Program of China award no. 2018YFC1312103 (Xia), and the American Cancer Society-Michigan Cancer Research Fund Postdoctoral Fellowship no. PF-16-245-01-DMC (Tiedemann). Research reported in this publication was also supported by The Hodson Trust (Baylin) and The Commonwealth Foundation (Baylin). The content is solely the responsibility of the authors and does not necessarily represent the official views of the granting organizations.


Van Andel Institute (VAI) is an independent nonprofit biomedical research and science education organization committed to improving the health and enhancing the lives of current and future generations. Established by Jay and Betty Van Andel in 1996 in Grand Rapids, Michigan, VAI has grown into a premier research and educational institution that supports the work of more than 400 scientists, educators and staff. Van Andel Research Institute (VARI), VAI's research division, is dedicated to determining the epigenetic, genetic, molecular and cellular origins of cancer, Parkinson's and other diseases and translating those findings into effective therapies. The Institute's scientists work in onsite laboratories and participate in collaborative partnerships that span the globe. Learn more about Van Andel Institute at

Van Andel Research Institute

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at